These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 25962100)

  • 21. Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
    Sherman EM; Worley MV; Unger NR; Gauthier TP; Schafer JJ
    Clin Ther; 2015 Sep; 37(9):1876-93. PubMed ID: 26319088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.
    Robertson J; Feinberg J
    Expert Opin Pharmacother; 2012 Jun; 13(9):1363-75. PubMed ID: 22594781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.
    Shah BM; Schafer JJ; Priano J; Squires KE
    Pharmacotherapy; 2013 Oct; 33(10):1107-16. PubMed ID: 23471741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
    Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
    J Antimicrob Chemother; 2018 Aug; 73(8):2120-2128. PubMed ID: 29905808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.
    Crauwels HM; Osiyemi O; Zorrilla C; Bicer C; Brown K
    HIV Med; 2019 May; 20(5):337-343. PubMed ID: 30873741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
    Negredo E; Clotet B
    Expert Opin Pharmacother; 2018 Jun; 19(8):929-934. PubMed ID: 29767543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients.
    López-Ruz MA; López-Zúñiga MA; Gonzalvo MC; Sampedro A; Pasquau J; Hidalgo C; Rosario J; Castilla JA
    PLoS One; 2018; 13(4):e0196257. PubMed ID: 29689065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
    Roberts O; Khoo S; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression.
    Antinori A; Cossu MV; Menzaghi B; Sterrantino G; Squillace N; Di Cristo V; Cattelan A; Focà E; Castagna A; Orofino G; Valenti D; D'Ettore G; Aprea L; Ferrara S; Locatelli ME; Madeddu G; Pontali E; Scerbo P; Rossetti B; Uglietti A; Termini R; Rucci F; Gori A; Mancusi D
    Patient; 2020 Jun; 13(3):375-387. PubMed ID: 32266663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
    Clotet B; Bellos N; Molina JM; Cooper D; Goffard JC; Lazzarin A; Wöhrmann A; Katlama C; Wilkin T; Haubrich R; Cohen C; Farthing C; Jayaweera D; Markowitz M; Ruane P; Spinosa-Guzman S; Lefebvre E;
    Lancet; 2007 Apr; 369(9568):1169-78. PubMed ID: 17416261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
    Yunquera-Romero L; Asensi-Díez R; Del Rio-Valencia JC; Muñoz-Castillo I; Castaño-Carracedo MA
    Rev Esp Quimioter; 2016 Dec; 29(6):308-317. PubMed ID: 27888600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simplification of ART in a patient living with multidrug resistant HIV-1: A case report using twice daily cobicistat and darunavir.
    Brizzi MB; Novak RM; Chiampas TD
    Int J STD AIDS; 2019 Nov; 30(13):1333-1336. PubMed ID: 31631777
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
    Flynn P; Komar S; Blanche S; Giaquinto C; Noguera-Julian A; Welch S; Lathouwers E; Van de Casteele T; Kakuda TN; Opsomer M
    Pediatr Infect Dis J; 2014 Sep; 33(9):940-5. PubMed ID: 25361024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.
    Tseng A; Hughes CA; Wu J; Seet J; Phillips EJ
    Ann Pharmacother; 2017 Nov; 51(11):1008-1022. PubMed ID: 28627229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents.
    Sevinsky H; Tao X; Wang R; Ravindran P; Sims K; Xu X; Jariwala N; Bertz R
    Antivir Ther; 2015; 20(5):493-500. PubMed ID: 25361436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
    Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Fletcher CV; Acosta EP;
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):294-296. PubMed ID: 27103489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.
    Colbers A; Moltó J; Ivanovic J; Kabeya K; Hawkins D; Gingelmaier A; Taylor G; Weizsäcker K; Sadiq ST; Van der Ende M; Giaquinto C; Burger D;
    J Antimicrob Chemother; 2015 Feb; 70(2):534-42. PubMed ID: 25326090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.
    Lathouwers E; Wong EY; Luo D; Seyedkazemi S; De Meyer S; Brown K
    HIV Clin Trials; 2017; 18(5-6):196-204. PubMed ID: 29143565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.